Phio CEO to Speak at Wainwright Conference in New York in September

Sep 6, 2023 | Press Releases

He’ll address clinical trial progress in Phio’s lead product candidateMARLBOROUGH, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) — Phio Pharmaceuticals (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform...

Phio Pharmaceuticals Announces Dosing of First Patient in Collaborative Clinical Trial with AgonOx, Inc. and Providence Cancer Institute

Aug 21, 2023 | Press Releases

Trial targeting treatment of metastatic melanoma and other solid tumorsMARLBOROUGH, Mass., Aug. 21, 2023 (GLOBE NEWSWIRE) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform...

Phio Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 10, 2023 | Press Releases

MARLBOROUGH, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor...

Phio Pharmaceuticals Announces Closing of $4 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules

Jun 2, 2023 | Press Releases

MARLBOROUGH, Mass., June 2, 2023 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced...

Phio Pharmaceuticals Announces $4 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules

May 31, 2023 | Press Releases

MARLBOROUGH, Mass., May 31, 2023 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced...

Phio Pharmaceuticals Announces Initiation of Collaborative Clinical Trial with PH-762, AgonOx’s Tumor Infiltrating Lymphocyte Program (AGX148) and Providence Cancer Institute

May 24, 2023 | Press Releases

One of two newly announced clinical trials for its lead product candidate, PH-762 MARLBOROUGH, Mass., May 24, 2023 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is...